Figure 1.
Kaplan-Meier estimate of progression-free survival (PFS) in mCRC patients with regorafenib A and between LC and RC groups B.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.